Thriving with Diabetes In the mHealth Era LabStyle Innovations Corp. (OTCQB:DRIO)
Disclaimer Regarding Forward-Looking Statements This presentation of LabStyle Innovations Corp. (the “ Company ” ) and statements of the Company ’ s management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "seek," "intend," "believe," "plan," "estimate," "expect," " anticipate“, ‘will”, “would” and other similar expressions all denote forward-looking statements within the meaning of the Act. Factors that could cause or contribute to such differences include the Company ’ s compliance with regulatory requirements, the Company ’ s status as a new public company, the impact of current and any future competition, as well as other factors and risks discussed in the Company's filings (including the results of the company’s commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by Company management or its agents have been prepared by Company management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to the future performance of the Company. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles. www.mydario.com
Executive Summary Public OTC (OTCQB:DRIO) • Company Unique combination of medical device • and Health IT solution. Diabetes – Diagnostic $12B + $254B • Market Extend to other chronic disease • Multiple revenue streams (disposable) • Product Unique patent portfolio • Digitalizing the monitoring market • Post reimbursement in Europe • Success in initial launch • Opportunity Use of proceeds – supply on existing • demand www.mydario.com
Flagship: Dario Personalized Smart Meter for Diabetes Almost 10% of Americans today 1 in 3 American adults by 2050 The 5 th leading cause of death in the world www.mydario.com
Medical Companies Have Spent Millions To Improve This Pack Traditional Glucose Meter www.mydario.com
Patients Still Have to Manage Their Own Condition Most of the Time 4 hours Visit Doctor 8,756 Hours Alone Patients need to take decisions by their own day by day and hour by hour www.mydario.com
To Manage Diabetes Effectively You Need a Combination of: Insight Motivation Tools While traditional medical device focus mainly on tools www.mydario.com
Dario Provides Diagnostic Device combined with a software to support and personalize the treatment Compact Tiny blood sample Highly accurate All-in-one device Automatically log & monitor Actionable alerts A1C estimates www.mydario.com
Value to Patients Smart Meter Simple to use, Smart Meter™ Plugs into smartphone Pocket-sized all-in-one Insight Insight & Disease Management Personal pattern recognition & Decision support Support You’re not alone Peer & Professional support www.mydario.com
Value to Payers Better testing Savings Better care & compliance & prevention = = Digitalizing the test strip market – cost saving www.mydario.com
Value to Supporters Easier monitoring & remote support Parents & children Adults & older parents Caregivers & PWDs www.mydario.com
Multiple Revenue Streams Out of pocket & reimbursement • Device & Disposable Strips (razorblade model) • Disposables Healthcare professionals - licenses • Software Payer risk-management & cost • Platform reduction Clinical studies, trial recruitment • Data Partnerships • Monetization www.mydario.com
Disposable – Growing Market $27b (Up 170%) $12b 2022 2013 www.mydario.com
Value Creation Flow Launch USA Multi Revenue Streams Extend 6 countries Launch Canada UK Australia CE NZ Holland Mark Italy Q4 Q2 Q4 Q1 Q1 Q3 2014 2015 www.mydario.com
Penetration by Q2/2015 New Zealand, UK, Italy 7 countries USA, Canada, Australia, Netherlands Diabetes 38M patients Population 7.4M insulin dependent Potential 0.2% of the insulin dependent population is 62K penetration users 2015 www.mydario.com
Competitive Advantage BlueStar MySugr Glooko iBGStar Dario WellDoc Only App Software Platform Only App Only iOS Embedded Medical Device Smart Insight Real Time Real Time Data Capture Dario TM : The Only Medical Device & Real-Time Software Solution www.mydario.com
Dario Direct Via Distributors B2C B2B Digital Marketing Sales Force App Users Healthcare Professionals www.mydario.com
UK Launch - Case Study Good Feedback – Strong Demand Dario is branded as personalized and patient oriented Digital marketing is very effective Build fast strong community www.mydario.com
UK – Users Testimonial www.mydario.com
Why Dario Why Now • Disposable – Low hanging fruit – Existing market with existing codes – Reimbursement approved. • Very big potential around the data and software • Shortly after launch (weeks) • 1,300 device users • 16,000 App Downloads • Very good market feedback – high demand • High quality standards (top 30% in the market) • Accuracy – compliance with new standards • Rich patent portfolio • 8 pending, 1 granted, 3 utility model • Major patent on medical device integration into smartphone www.mydario.com
Movie https://www.youtube.com/watch?v=_XnJzQhcfpI www.mydario.com
Experienced Management Team 20 years of experience in building product organizations Erez Raphael – from Design to commercialization. Formerly with CEO & President Amdocs (NYSE: DOX) and Nokia-Siemens. Gadi Levin Seasoned executive with significant experience in publicly listed companies, capital market financings, CFO accounting and financial management. Former SVP Clinical and Regulatory Affairs at Given Shosh Friedman Imaging (NASDAQ:GIVN). More than 20 years in clinical, VP Clinical and Regulatory regulatory affairs and QA systems. Affairs (FRAP RAC) Entrepreneur and patient advocate who has dedicated Entrepreneur and patient advocate who has dedicated his career to using technology to improve health and David Edelman his career to using technology to improve health and happiness. President of Diabetes Daily, a leading online happiness. President of Diabetes Daily, a leading online Director Product Strategy community and educational platform. community and educational platform. Over 16 years of executive leadership in the Medical Over 16 years of executive leadership in the Medical Eran Kurman Device Industry. He has extensive experience in global Device Industry. He has extensive experience in global strategic marketing, business development, and clinical strategic marketing, business development, and clinical VP, Global Strategy development knowledge. development knowledge. More than 15 years of software business experience, Dror Bacher including managing positions in product development at both mobile and semi-conductor companies. VP, R&D www.mydario.com
Board of Directors Seasoned entrepreneur and investor Oren Fuerst, PhD Founder of Tevel Global & Strategic Models Former faculty Columbia Business School. Extensive experience in Chairman & Co-Founder medical devices and data management CEO, Executive Vice-Chairman, Conference of Major Malcolm Hoenlein American Jewish Organizations. Director, Council of Director Foreign Relations Currently serves as President, CFO and board director Dennis McGrath of PhotoMedex, Inc. (NasdaqGS: PHMD,) joining the Director company in 2000 World-renowned urologist and researcher. Co-founded Dr. Steven Kaplan numerous technology initiatives, including MediData Solutions (NASDAQ:MDSO) the largest clinical trials data Director management company. Serves on the board of directors of multiple technology companies, including Powermat, Espro-Accoustiguide Prof. Richard Stone Group, Wellsense Technologies, NanoX Imaging and Check-Cap. Cofounded Lev Pharmaceuticals, Inc. which Director was sold to ViroPharma in 2008 for nearly $450 million in upfront consideration . Erez Raphael 20 years of experience in building product organizations – from Design to commercialization. Formerly with CEO & President Amdocs (NYSE: DOX) and Nokia-Siemens. www.mydario.com
Recommend
More recommend
